<DOC>
	<DOCNO>NCT02699008</DOCNO>
	<brief_summary>High on-treatment platelet reactivity adenosine diphosphate important reason cause ischemic event antiplatelet therapy . Using single test definite HPR may miss `` true HPR '' estimate HPR , may lead randomized trial fail . It know whether combined multiple platelet function test could assist ensure '' ture '' HPR improve clinical outcome .</brief_summary>
	<brief_title>High On-treatment Platelet Reactivity Identified Multiple Platelet Function Assay</brief_title>
	<detailed_description>This single-center , randomize , prospective study . ACS patient undergo PCI treat clopidogrel aspirin include . 3-5th day prescription clopidogrel , platelet function test simultaneously three method : MPAADP Light transmittance aggregometry（LTA） , MAADP Thrombelastography ( TEG ) , CTP2Y Innovance PFA-200 . According three result（Two three three result higher cutoff value identify HPR , MPALTA &gt; 50 % ; MAADP &gt; 47mm ; CTP2Y &lt; 106s）.Patients define HPR ( n=125 ) unHPR ( n=232 ) , HPR patient divide HPR-Ticagrelor ( HPR-T ) HPR-Clopidogrel ( HPR-C ) randomize . HPR-T group ( n=77 ) patient ' antiplatelet agent change ticagrelor , unHPR HPR-C group keep unchanged ( Clopidogrel ) . The major adverse cardiovascular event ( MACE ) record 1 year Follow-up .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>ACS patients（UAP ; USTEMI , STEMI） Undergoing PCI Oral antiplatelet therapy Stable CAD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>clopidogrel；antiplatelet therapy</keyword>
</DOC>